Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ANS014004 plus EGFR-TKI in EGFR-mutant advanced or metastatic non-small cell lung cancer
CTR20252864Phase 2Active
- Sponsor
- Avistone Biotechnology Co., Ltd.
- Start
- Nov 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ANS014004 and andamertinib in non-small cell lung cancer (NSCLC), sponsored by Avistone Biotechnology Co., Ltd. Primary endpoints: Dose-limiting toxicity incidence, Safety and tolerability and 1 more. Started Nov 2025; status: active.
02
Drugs
ANS014004andamertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20252864.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252864.